Description: Vifor Pharma AG researches, develops, produces, and markets pharmaceutical products in Switzerland, rest of Europe, the United States, and internationally. The company offers Ferinject/Injectafer, a solution of ferric carboxymaltose used in the intravenous treatment of iron deficiency; Mircera, a long-acting erythropoiesis-stimulating agent to treat symptomatic anaemia associated with the chronic kidney disease (CKD); Venofer, a solution for iron sucrose used in the intravenous treatment of iron deficiency; and Invokana to treat diabetic kidney disease. It provides Retacrit to treat anaemia due to CKD; Velphoro, a non-calcium, iron-based, and chewable phosphate binder to control the phosphate levels in the blood of adults with CKD; and Veltassa, a sodium-free potassium binder to treat hyperkalaemia in adult patients. The company offers Maltofer, an oral iron polymaltose complex for infants, children, adolescents, and pregnant woman; Broncho-Vaxom, to treat recurrent respiratory infections; Uro-Vaxom to treat recurrent urinary tract infections; Doxium, an oral treatment for diabetic retinopathy and haemorrhoidal syndrome; and Uro-Vaxom to treat recurrent urinary tract infections. It provides Rayaldee, which is in pre commercial stage to treat secondary hyperparathyroidism in patients with CKD; Avacopan, which is in pre commercial stage to treat orphan and rare renal diseases; Vadadustat, which is Phase III clinical trials to treat anaemia due to CKD; CR845, which is in Phase III clinical trials to treat CKD disease-associated pruritus; CCX140, which is in Phase II clinical trials to treat patients with focal segmental glomerulosclerosis; and VIT-2763, which is in Phase II clinical trial to treat beta-thalassemia. Vifor Pharma AG has a strategic partnership with Fresenius Kabi. The company was formerly known as Galenica AG and changed its name to Vifor Pharma AG in April 2017. Vifor Pharma AG was founded in 1872 and is headquartered in Zurich, Switzerland.
Home Page: www.viforpharma.com
Rechenstrasse 37
Sankt Gallen,
9014
Switzerland
Phone:
41 58 851 80 00
Officers
| Name | Title |
|---|---|
| Mr. Alexandros Sigalas | Acting CFO & Head of IT & Admin. |
| Mr. Frederic Zwahlen | Head of Technical Operations |
| Mr. Julien Vignot | Head of Investor Relations & Treasury |
| Dr. Oliver P. Kronenberg | Group Gen. Counsel |
| Ms. Nathalie Ponnier | Global Head Corp. Communications |
| Mr. Michael Puri | Chief HR Officer |
| Dr. Christoph Springer | Chief Strategy Officer |
| Dr. Thomas Kaspar | Head of Global Quality Management |
| Dr. Thierry Teil | Head of Global Medical Affairs |
| Ms. Carolina Ponchione | Head of Exec. Search & Employer Branding |
Exchange: PINK
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 18.6916 |
|---|---|
| Trailing PE: | 78.3367 |
| Price-to-Book MRQ: | 3.2212 |
| Price-to-Sales TTM: | 6.3915 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 2200 |